| 2008-05-01: |
Coversyl( R ) Protects Hypertensive Patients Against New - Onset Diabetes
Paris ( PRN/ots ) - - New Analysis of ASCOT - BPLA Data Identifies Major Predictors of NOD Among Hypertensives A new analysis of data from the landmark Anglo - Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm ( ASCOT - BPLA ) published today in Diabetes Care has identified (...) |
| 2008-04-30: |
Printed Electronics Europe 2008: Germany Pioneering New Innovations
Dresden, March ( na Originaltextservice ) - Hand - held electronic books, super sharp flat - screen TVs, and solar cells that can be printed like newspaper: These are some of the innovations taking place in Germany and being featured at Printed Electronics Europe 2008, ( April (...) |
| 2008-04-29: |
Journalist Invitation - International Media Webcast
Ingelheim, Germany ( PRN/ots ) - The science of sexual desire No doubt you've written about it before: Sex - an ever - present topic in newspapers and magazines. Yet, despite the genuine interest in sex, little focus is given to the science behind it (...) |
| 2008-04-29: |
Imaging Results From the ADAGIO - LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Quebec City, Canada ( PRN/ots ) - At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO - LIPIDS presented the key findings of a one year trial aiming at further studying (...) |
| 2008-04-26: |
Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
Basel, Switzerland ( PRN/ots ) - - Roche Also Provides Comment on Results of "IDEAL" Trial Roche today announced that compelling new data from three studies indicate that chronic hepatitis C patients who received PEGASYS( R ) ( peginterferon alfa - 2a ) plus COPEGUS( R ) ( ribavirin ) had a greater chance (...) |
| 2008-04-26: |
Roche's R1626, First - in - Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End - of - Treatment Response in Phase IIa Study
Basel, Switzerland ( PRN/ots ) - - R1626 Also Shows a High Barrier to the Development of Resistance Roche's investigational treatment for hepatitis C, R1626, has shown an impressive end - of - treatment response rate when given in combination with PEGASYS( R ) ( peginterferon alfa - 2a ) and COPEGUS( R ) ( ribavirin ). (...) |
| 2008-04-26: |
New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment Response That Comes as Close to a Cure as Possible
Basel, Switzerland ( PRN/ots ) - - No Nucleoside/Nucleotide Analogue Treatments Have Shown Similar Results New data revealed today show that a significant number of patients with chronic hepatitis B virus infection who received PEGASYS( R ) ( peginterferon alfa - 2a ) treatment achieved clearance of a blood antigen (...) |
| 2008-04-25: |
Data Suggests Promising Overall Survival and Progression - Free Survival With VARGATEF( TM ) ( BIBF 1120 )
Ingelheim, Germany ( PRN/ots ) - - For non - US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor( 1 ) BIBF 1120 (...) |
| 2008-04-24: |
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid - Induced Constipation in Advanced - Illness Patients
COLLEGEVILLE, Pennsylvania and TARRYTOWN, New York, April 24 ( PRN/ots ) - - - Final Decision from European Commission Expected by Mid - 2008 Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), and Progenics Pharmaceuticals, Inc. ( Nasdaq: PGNX ), today announced that the companies have received a positive (...) |
| 2008-04-24: |
More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
Collegeville, Pennsylvania ( PRN/ots ) - - Wyeth Withdraws European Application Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it is withdrawing its application for an extension to the European Marketing Authorization for TYGACIL( R ) ( tigecycline ). This extension sought approval of TYGACIL for (...) |
| 2008-04-22: |
Dosing for RVX - 208 Phase 1a Clinical Study Completed
Calgary, Canada ( PRN/ots ) - - Phase 1a Study Objectives Were Met - TSX Exchange Symbol: RVX Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX:RVX ) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead (...) |
| 2008-04-18: |
Herceptin( R ) Helps Eradicate HER2 - Positive Breast Tumours When Given Before Surgery
BERLIN - European Breast Cancer Conference ( EBCC ), April 18 ( PRN/ots ) - - - For Non - UK and Non - US Media Only - Herceptin Offers Women With HER2 - Positive Breast Cancer the Best Chance of a Cure New data presented today as part of a late (...) |
| 2008-04-17: |
New Data Confirm Pramipexole ( Mirapexin( R )/Sifrol( R ) ) Can Significantly Reduce Sleep Disturbance for People With Restless Legs Syndrome ( RLS )
Ingelheim, Germany ( PRN/ots ) - - For Healthcare Media Outside the U.S.A. - Studies Demonstrate Positive and Rapid Impact of Pramipexole on the Core Symptoms of Restless Legs Syndrome and Sleep Disturbance A new study has shown that pramipexole ( Mirapexin( R )/Sifrol( R ) ) can significantly reduce (...) |
| 2008-04-16: |
European Regulatory Agency Grants Orphan Status to Morphotek( R )'s Farletuzumab and MORAb - 009
Exton, Pennsylvania ( PRN/ots ) - - Upon Marketing Authorization Orphan Status Would Provide for Ten Years of Market Exclusivity in the European Union for Both Investigational Treatments Morphotek( R ), Inc., a subsidiary of Eisai Corporation of North America, announced today that the European Commission has (...) |
| 2008-04-14: |
New Powerful Antihypertensive MicardisPlus( R ) 80/25 ( 80mg telmisartan/25mg hydrochlorothiazide ) Approved by EU Commission
Ingelheim, Germany ( PRN/ots ) - - For Medical Media, Outside the US Only Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus( R ) 80/25 in all 27 EU (...) |
| 2008-04-14: |
Botaneco Announces Launch of Second Generation Oleosome Product
Calgary, Canada ( PRN/ots ) - - Natural Hydresia( TM ) G2 Offers Enhanced Formulation Flexibility With a Globally Accepted Preservative System Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc. ( TSX: SBS ), focused on the development and commercialization of oleosome technology in personal care, OTC and (...) |
| 2008-04-11: |
Status of the E2007 ( perampanel ) Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications
Tokyo, Japan ( PRN/ots ) - E2007 ( perampanel ) is a first - in - class, orally administered, highly selective non - competitive AMPA - type glutamate receptor antagonist, in development by Eisai ( TSE:4523 ) for several indications, including Parkinson's disease, neuropathic pain, epilepsy, multiple sclerosis and migraine prophylaxis. The AMPA receptor (...) |
| 2008-04-10: |
Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide
Istanbul, Turkey ( PRN/ots ) - - Multi - national study will follow 60,000 women for 5 years Nearly 60,000 women aged 55 years and older have enrolled in a landmark, multi - national study that will focus on the management of osteoporosis across the globe. (...) |
| 2008-04-07: |
New Abbott Kaletra( R ) ( lopinavir/ritonavir ) Lower - Strength Tablet for Pediatric Use Approved in Europe
Abbott Park, Illinois ( PRN/ots ) - - Lopinavir/ritonavir Tablet is the First and Only Co - Formulated Protease Inhibitor Tablet Approved for Use in Children with HIV Abbott announced today that it has received marketing authorization from the European Commission for the new, lower - (...) |
| 2008-03-31: |
New Data Showed ACTOS( R ) ( pioglitazone HCl ) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Chicago ( PRN/ots ) - - Data Expands Body of Evidence in High Risk Population Using IVUS, a Unique Marker for Coronary Atherosclerosis New data from a clinical trial using intravascular ultrasound ( IVUS ) technology found that in patients living with type 2 diabetes, ACTOS( R ) ( pioglitazone (...) |
| 2008-03-31: |
Landmark Trial ONTARGET( R ) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High - Risk Cardiovascular Population. From ONTARGET( R ) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event
Ingelheim, Germany ( PRN/ots ) - - Results of 25,620 Patient Study ONTARGET( R ) ( ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial ) Presented Today at the 57th Annual Scientific Session of the American College of Cardiology( 1 ) - For Non - US Healthcare Media The results (...) |
| 2008-03-31: |
First Statin Monotherapy to Achieve Regression of Coronary Atherosclerosis by Angiography in a Major Clinical Study
London ( PRN/ots ) - CRESTOR( TM ) ( rosuvastatin ) is the only statin to show regression of coronary atherosclerosis in a major clinical study. That result, which was based on intravascular ultrasound ( IVUS ) data from the ASTEROID study, has now been expanded upon by quantitative coronary angiography ( QCA ) (...) |
| 2008-03-31: |
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Indianapolis ( PRN/ots ) - - Late - stage IDENTITY study of once - daily, oral agent is now enrolling patients Eli Lilly and Company ( NYSE: LLY ) has announced today the start of a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the (...) |
| 2008-03-27: |
New Studies Confirm the Benefits of Dapoxetine as a Treatment of Premature Ejaculation
European Association of Urology ( EAU ), MILAN, March 27 ( PRN/ots ) - - - Pivotal Efficacy Data Reinforced by Female Partners; Robust Safety Data Presented New data presented for the first time today at EAU demonstrate the benefits for men with premature ejaculation ( PE ) and (...) |
| 2008-03-27: |
Pieris raises EUR 25 M ( US$ 38 M ) in Series B financing round / New investment round led by OrbiMed Advisors, world?s largest healthcare investment firm
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round. Led by new investor OrbiMed Advisors LLC, a major global fund (...) |
| 2008-03-26: |
SemBioSys Initiates Toxicology Study for Safflower - Produced Insulin
Calgary, Canada ( PRN/ots ) - - Initiation of Study Puts Company on Track for Phase I/II Trial SemBioSys Genetics Inc. ( TSX: SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has initiated (...) |
| 2008-03-17: |
ALK - Abelló, the Makers of GRAZAX( R ), Present Successful Phase III Clinical Study Results with Children
Horsholm, Denmark ( PRN/ots ) - - Results Show Highly Significant Effect on Rhinoconjunctivitis ( Hay Fever ) and Asthma Symptoms in Children from age 5 to 16 Years - old ALK - Abelló yesterday presented successful Phase III clinical study results with GRAZAX( R ) in children at the American (...) |
| 2008-03-13: |
Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
Biocitech Park, Romainville, France ( PRN/ots ) - Cellectis SA ( NYSE: ALCLS ), a world leader in rational genome engineering, has announced today that it filed a patent infringement lawsuit against Precision BioSciences, Inc. in the United States District Court for the Eastern District of North (...) |
| 2008-03-13: |
Enabling the Mobile Workforce (...) Entrust Deploys Strong Authentication for German Health Insurance Expert
Dallas ( PRN/ots ) - - Entrust IdentityGuard OTP tokens secure access to corporate resources for remote workforce Germany - based Universa, the country's oldest private health insurance organization, sought a trusted method to enable secure enterprise access and communication via a multifactor authentication solution. In the (...) |
| 2008-03-12: |
More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
Madison, New Jersey ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it would need to conduct additional clinical studies to address questions from the Committee for Medicinal Products for Human Use ( CHMP ) regarding the risk - benefit profile (...) |
| 2008-03-11: |
Roche Creates "The Amazing Kidnerellis!" Animation to Boost Public Awareness of Chronic Kidney Disease on World Kidney Day
Basel, Switzerland ( PRN/ots ) - The life - sustaining activities of our kidneys tend to go unnoticed, until they falter or fail. World Kidney Day ( http://www.worldkidneyday.org ) on March 13th seeks to address this knowledge gap and to boost public awareness of how vital kidney health (...) |
| 2008-03-05: |
Don't Leave Your Vision to Chance on World Glaucoma Day
London ( PRN/ots ) - - Leading Glaucoma Experts Act to Help Prevent Vision Loss as 50 Percent of Patients Remain Undiagnosed LONDON, March 5 /PRNewswire/ - - On the first World Glaucoma Day ( March 6, 2008 ), leading glaucoma experts globally are asking those who may (...) |
| 2008-03-05: |
New 300mg Loading Dose Tablet for Plavix( R ) Receives Positive Opinion From the European Committee for Medicinal Products ( CHMP )
Paris and Princeton, New Jersey ( PRN/ots ) - - A New Step Forward May Help Increase Appropriate Early Use of Plavix( R ) by Simplifying Administration in Acute Coronary Syndrome Patients Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) and Bristol - Myers Squibb Company ( NYSE: BMY ) announced (...) |
| 2008-03-05: |
MIRCERA( R ) Successfully Corrects Anaemia With a Smooth and Steady Rise in Haemoglobin Levels in Line With Current Guidelines
Basel, Switzerland ( PRN/ots ) - The results of a large - scale study of patients with chronic kidney disease ( CKD ) who are not on dialysis, and who have never received a treatment for anaemia before, has found that MIRCERA given at an extended dosing interval once (...) |
| 2008-02-26: |
Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
Lyon, France ( PRN/ots ) - - Six Million Doses of Stamaril( TM ) Vaccine Shipped in Record Time to Brazil and Paraguay Sanofi Pasteur, the vaccines division of the Sanofi - aventis Group, announced today that six million doses of Stamaril( TM )( 1 ) yellow fever vaccine have been shipped (...) |
| 2008-02-22: |
Astellas Receives Positive Opinion From CHMP for Mycamine( R ) for the Treatment of Serious Fungal Infections
Staines, England ( PRN/ots ) - - New Treatment Option Contributes to Fight Against Healthcare Associated Infections Astellas Pharma Europe Ltd( i ) announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) issued a positive opinion by consensus, (...) |
| 2008-02-20: |
Siemens Healthcare Announces Exclusive Partnership With Prowess Inc.
Concord, California ( PRN/ots ) - - Plans to Integrate Treatment Planning System with Oncology Solutions Technology Siemens Healthcare ( www.usa.siemens.com/healthcare ) announces an exclusive partnership with Prowess Inc. to develop advanced radiation oncology treatment planning software for integration into Siemens' linear accelerators. The combination of Prowess' (...) |
| 2008-02-14: |
Major International Diabetes Study Does not Confirm Increased Risk of Death Reported by US Trial
Paris ( PRN/ots ) - - Preliminary Findings from the Largest - Ever Study of Treatments for Diabetes Provide no Evidence That Intensive Treatment to Lower Blood Glucose ( Sugar ) Increases Risk of Death Interim results from the ADVANCE Study, involving 11,140 high - risk patients with type (...) |
| 2008-02-14: |
GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon - Alpha Aimed at Hepatitis C
Paris ( PRN/ots ) - - GenOdyssee has Received Notice of Allowance of United States Patent Application Covering it's Lead HCV Interferon - Alpha Product GEA007.1, a Natural Protein With Improved Anti - HCV Genotype 1 Activity GenOdyssee S.A., a biotechnology company dedicated to the discovery and development (...) |
| 2008-02-14: |
Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
Lyon, France ( PRN/ots ) - - Scientific Advances in Vaccine Research may Lead to Improved Vaccine Against Leading Cause of Death in Developing Countries Sanofi Pasteur, the vaccines division of the sanofi - aventis Group, announced today that it has signed a collaborative research and (...) |
| 2008-02-13: |
Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
Basel, Switzerland ( PRN/ots ) - - Results of This Trial Further Confirm the Benefit Avastin Brings to Patients With Breast Cancer. Roche announced today that a phase III study in metastatic breast cancer investigating Avastin ( bevacizumab ) in combination with docetaxel chemotherapy compared to docetaxel (...) |
| 2008-02-04: |
Acrongenomics Acquires Equity Stake in Molecular Vision
Geneva ( PRN/ots ) - Acrongenomics, Inc. ( OTC: AGNM ) is pleased to announce that they have acquired a 10.9 Prozent interest in Molecular Vision Limited, on a fully diluted basis. The cash consideration will be used by Molecular Vision for working capital and to further develop its (...) |
| 2008-02-04: |
Promising Phase 3 Data for Ustekinumab ( CNTO 1275 ) in Long - Term Improvement of Chronic Plaque Psoriasis
San Antonio, Texas ( PRN/ots ) - - New Findings From a Second Pivotal Phase 3 Study Show Subjects Receiving Ustekinumab Every 12 weeks Maintained Improvement From Psoriasis Through One Year One - year data from the second double blind, placebo - controlled Phase 3 study PHOENIX (...) |
| 2008-02-04: |
EU Grants Broad Approval of Xeloda for Patients With Metastatic Colorectal Cancer
Basel, Switzerland ( PRN/ots ) - - Many More Patients Can Now Benefit From Oral Chemotherapy That Significantly Reduces Treatment Time Roche announced today that the European Commission has approved its oral chemotherapy Xeloda ( capecitabine ) for the treatment of metastatic colorectal cancer in combination with (...) |
| 2008-02-01: |
Abbott Gains Reimbursement for XIENCE( TM ) V Drug Eluting Stent in France
Abbott Park, Illinois ( PRN/ots ) - - Improved Medical Benefit Rating Granted for XIENCE V from French Health Authority Abbott ( NYSE: ABT ) today announced that it has received reimbursement approval in France for its XIENCE( TM ) V Everolimus Eluting Coronary Stent System, the first drug (...) |
| 2008-01-28: |
EMEA Validates Wyeth Application to Expand the European Label of TORISEL
Maidenhead, England ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE ), announced today that the European Medicines Agency ( EMEA ) has validated the marketing authorisation application for Torisel( R ) ( temsirolimus ) for treating relapsed and/or refractory mantle cell lymphoma ( MCL ), a rare type of non - Hodgkin's (...) |
| 2008-01-28: |
Abbott's Kaletra( R ) and Aluvia( R ) ( lopinavir/ritonavir ) New Lower - Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Abbott Park, Illinois ( PRN/ots ) - - Lopinavir/ritonavir tablet is the first and only co - formulated protease inhibitor tablet approved for use in children with HIV Abbott ( NYSE: ABT ) announced today that the European Committee for Medicinal Products for Human Use ( CHMP ), (...) |
| 2008-01-28: |
Clexane( R )/Lovenox( R ) Approved in Japan
Paris ( PRN/ots ) - Sanofi - aventis announced today that the anticoagulant Clexane( R ) ( enoxaparin sodium injection ) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the prevention of venous thromboembolism ( VTE ) in patients undergoing orthopaedic surgery of the lower (...) |
| 2008-01-28: |
Many More Patients Can Now Benefit From Avastin's Proven Survival Benefits
Basel, Switzerland ( PRN/ots ) - - Avastin Receives Broad Label Extension in Europe for the Treatment of Patients With Metastatic Colorectal Cancer Roche announced today that the European Commission ( EC ) has given its approval for the significantly wider use of its anti - angiogenic agent (...) |
|
|
back...
1
2
3
4
5
6
7
8
9
10
11
more... |
